ECSP11011415A - Piperidinas sustituidas como antagonistas de ccr3. - Google Patents
Piperidinas sustituidas como antagonistas de ccr3.Info
- Publication number
- ECSP11011415A ECSP11011415A EC2011011415A ECSP11011415A ECSP11011415A EC SP11011415 A ECSP11011415 A EC SP11011415A EC 2011011415 A EC2011011415 A EC 2011011415A EC SP11011415 A ECSP11011415 A EC SP11011415A EC SP11011415 A ECSP11011415 A EC SP11011415A
- Authority
- EC
- Ecuador
- Prior art keywords
- ccr3
- antigonist
- piperidins
- replaced
- present
- Prior art date
Links
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 title abstract 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Objeto de la presente invención son compuestos novedosos sustituidos de la fórmula 1,en la que A, R1, R2, R3 y R4 se definen como en la descripción. Otro objeto de la presente invención es proporcionar antagonistas de CCR3, más particularmente proporcionar composiciones farmacéuticas que comprenden un vehículo farmacéuticamente aceptable y una cantidad terapéuticamente eficaz de al menos uno de los compuestos de la presente invención o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16270509P | 2009-03-24 | 2009-03-24 | |
US31671310P | 2010-03-23 | 2010-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011415A true ECSP11011415A (es) | 2011-11-30 |
Family
ID=42136100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011415A ECSP11011415A (es) | 2009-03-24 | 2011-08-24 | Piperidinas sustituidas como antagonistas de ccr3. |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP2411372B1 (es) |
JP (1) | JP5744003B2 (es) |
KR (1) | KR101665955B1 (es) |
CN (1) | CN102361858B (es) |
AU (1) | AU2010229975B2 (es) |
BR (1) | BRPI1009854A2 (es) |
CA (1) | CA2753825C (es) |
CL (1) | CL2011002278A1 (es) |
CO (1) | CO6450678A2 (es) |
CR (1) | CR20110524A (es) |
DO (1) | DOP2011000297A (es) |
EC (1) | ECSP11011415A (es) |
ES (1) | ES2488821T3 (es) |
GT (1) | GT201100241A (es) |
HK (1) | HK1166798A1 (es) |
IL (1) | IL214858A (es) |
MX (1) | MX2011010049A (es) |
MY (1) | MY169288A (es) |
NZ (1) | NZ594923A (es) |
PE (1) | PE20120519A1 (es) |
RU (1) | RU2524573C2 (es) |
SG (1) | SG174211A1 (es) |
WO (1) | WO2010111348A1 (es) |
ZA (1) | ZA201106511B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
PE20131095A1 (es) | 2010-07-16 | 2013-10-27 | Abbvie Bahamas Ltd | Ligandos fosfina para reacciones cataliticas |
US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
JP5819959B2 (ja) | 2010-07-16 | 2015-11-24 | アッヴィ・バハマズ・リミテッド | 抗ウイルス性化合物を調製するための方法 |
US9248193B2 (en) | 2011-03-18 | 2016-02-02 | Abbvie Inc. | Formulations of phenyl uracil compounds |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7316900A (en) * | 1999-09-20 | 2001-04-24 | Fuji Photo Film Co., Ltd. | Compounds for fluorescence labeling |
CN1158299C (zh) * | 1999-09-22 | 2004-07-21 | 阿文蒂斯药物德国有限公司 | 取代的4-苄基氨基喹啉、其制备方法、含有这些化合物的药物及其应用 |
DE10051981A1 (de) * | 2000-10-20 | 2002-05-02 | Bayer Ag | Substituierte Phenyluracile |
CA2653924A1 (en) * | 2006-05-30 | 2007-12-06 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
RU2542099C2 (ru) * | 2007-09-17 | 2015-02-20 | Эббви Бахамаз Лтд. | N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv) |
CA2976793A1 (en) * | 2007-09-17 | 2009-03-26 | Abbvie Ireland Unlimited Company | Uracil or thymine derivative for treating hepatitis c |
AU2009273327A1 (en) * | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
-
2010
- 2010-03-24 WO PCT/US2010/028433 patent/WO2010111348A1/en active Application Filing
- 2010-03-24 MX MX2011010049A patent/MX2011010049A/es active IP Right Grant
- 2010-03-24 SG SG2011063179A patent/SG174211A1/en unknown
- 2010-03-24 AU AU2010229975A patent/AU2010229975B2/en active Active
- 2010-03-24 PE PE2011001686A patent/PE20120519A1/es active IP Right Grant
- 2010-03-24 KR KR1020117024825A patent/KR101665955B1/ko active IP Right Grant
- 2010-03-24 BR BRPI1009854-2A patent/BRPI1009854A2/pt not_active Application Discontinuation
- 2010-03-24 RU RU2011142757/04A patent/RU2524573C2/ru active
- 2010-03-24 JP JP2012502196A patent/JP5744003B2/ja active Active
- 2010-03-24 ES ES10711968.7T patent/ES2488821T3/es active Active
- 2010-03-24 EP EP10711968.7A patent/EP2411372B1/en active Active
- 2010-03-24 CN CN201080013374.7A patent/CN102361858B/zh active Active
- 2010-03-24 MY MYPI2011004471A patent/MY169288A/en unknown
- 2010-03-24 NZ NZ594923A patent/NZ594923A/xx unknown
- 2010-03-24 CA CA2753825A patent/CA2753825C/en active Active
-
2011
- 2011-08-24 EC EC2011011415A patent/ECSP11011415A/es unknown
- 2011-08-28 IL IL214858A patent/IL214858A/en active IP Right Grant
- 2011-09-06 ZA ZA2011/06511A patent/ZA201106511B/en unknown
- 2011-09-14 CL CL2011002278A patent/CL2011002278A1/es unknown
- 2011-09-20 GT GT201100241A patent/GT201100241A/es unknown
- 2011-09-21 CO CO11123197A patent/CO6450678A2/es active IP Right Grant
- 2011-09-23 DO DO2011000297A patent/DOP2011000297A/es unknown
- 2011-10-04 CR CR20110524A patent/CR20110524A/es unknown
-
2012
- 2012-08-01 HK HK12107568.3A patent/HK1166798A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES2488821T3 (es) | 2014-08-29 |
CA2753825A1 (en) | 2010-09-30 |
CR20110524A (es) | 2012-01-19 |
EP2411372B1 (en) | 2014-07-23 |
IL214858A0 (en) | 2011-11-30 |
JP5744003B2 (ja) | 2015-07-01 |
RU2524573C2 (ru) | 2014-07-27 |
EP2411372A1 (en) | 2012-02-01 |
PE20120519A1 (es) | 2012-06-03 |
WO2010111348A1 (en) | 2010-09-30 |
MY169288A (en) | 2019-03-21 |
CN102361858A (zh) | 2012-02-22 |
CA2753825C (en) | 2017-10-17 |
KR101665955B1 (ko) | 2016-10-13 |
AU2010229975B2 (en) | 2015-05-21 |
KR20110137372A (ko) | 2011-12-22 |
GT201100241A (es) | 2015-08-19 |
MX2011010049A (es) | 2011-10-11 |
CO6450678A2 (es) | 2012-05-31 |
RU2011142757A (ru) | 2013-04-27 |
AU2010229975A1 (en) | 2011-09-29 |
JP2012521990A (ja) | 2012-09-20 |
SG174211A1 (en) | 2011-10-28 |
ZA201106511B (en) | 2012-05-30 |
IL214858A (en) | 2015-05-31 |
BRPI1009854A2 (pt) | 2015-08-25 |
CN102361858B (zh) | 2014-07-23 |
CL2011002278A1 (es) | 2012-03-09 |
DOP2011000297A (es) | 2011-10-15 |
NZ594923A (en) | 2013-11-29 |
HK1166798A1 (en) | 2012-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011427A (es) | Piperidinas sustituidas como antagonistas de ccr3. | |
UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
CR11683A (es) | Piridinas y pirazinas como inhibidores de p13k | |
NI201200089A (es) | INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. | |
ECSP11010880A (es) | Compuestos orgánicos | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
SV2011003855A (es) | Heteroarilos sustituidos | |
CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
DOP2009000278A (es) | Derivados de bencimidazol | |
ECSP11011415A (es) | Piperidinas sustituidas como antagonistas de ccr3. | |
UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
SV2010003459A (es) | Derivados de pirimidina 934 | |
CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
CO6331308A2 (es) | Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden | |
BRPI0924617A8 (pt) | Compostos heterociclicos de fenoximetila | |
CR20110093A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
GT200900309A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica | |
PE20170427A1 (es) | Peptidos como agonistas de la oxitocina | |
ECSP11011473A (es) | Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída | |
CO6361921A2 (es) | 3-aminociclopentancarboxamidas | |
DOP2012000078A (es) | Derivados de espirolactama y usos de los mismos | |
PE20141168A1 (es) | Derivados de pirazolidin-3-ona | |
ATE546448T1 (de) | Urotensin-ii-rezeptorantagonisten |